Drug Index

Entecavir

 
print

Mechanism :

By competing with the natural substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt): (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Upon activation by kinases, the drug can be incorporated into the DNA which has the ultimate effect of inhibiting the HBV polymerase activity.


Indication :

• Chronic hepatitis B virus infection


Contraindications :

Hypersensitivity, Patients with HIV who are not receiving HAART.


Dosing :

<2 years: Safety and efficacy not established. To be taken on an empty stomach.

>2 years: Nucleoside-naive: 0.5 mg orally every day. In lamivudine or telbivudine known resistant mutation: 1 mg orally every day.


Adverse Effect :

Fatigue, headache, dizziness, nausea, diarrhea, dyspepsia, vomiting, somnolence, insomnia, lactic acidosis, increased transaminases.


Interaction :

Drugs that reduce Renal Function or Compete for Active Tubular Secretion: Coadministration with entecavir may increase serum concentrations of either entecavir or the co administered drug.

Lamivudine, Adefovir Dipivoxil, or Tenofovir Disoproxil Fumarate: Coadministration with entecavir did not result in significant drug interactions.


07/18/2019 09:16:05 Entecavir
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0